IL6 and serum lipopolysaccharide activity: On the other hand, the Ezh2 inhibitor did not attenuate LPS-CLP mice, as indicated by the non-difference in survival analysis, organ damage (kidney and liver), endotoxemia, and bacteremia (Figure 9B–D,F,G), despite the reduction of cell-free DNA and serum cytokines (TNF-α, IL-6, and IL-10) in Ezh2 inhibitor-administered mice (Figure 9E,H–J).